ストックスクリーナーアプリを入手
2.94
3.29%
-0.10
アフターアワーズ：
2.95
0.01
+0.34%
前日終値:
$3.04
開ける：
$3.2
24時間の取引高:
11.66M
Relative Volume:
1.67
時価総額：
$2.15B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-3.0309
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
+21.49%
1か月 パフォーマンス:
+3.89%
6か月 パフォーマンス:
-52.04%
1年 パフォーマンス:
-19.45%
1日の値動き範囲:
$2.93
$3.30
1週間の範囲:
$2.28
$3.30
52週間の値動き範囲:
$2.28
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.94 | 2.15B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Finance
Why Did Immunitybio (IBRX) Go Down on Friday? - MSN
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
Why ImmunityBio, Inc. (IBRX) Dominated Last Week’s Rally - Insider Monkey
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK - MSN
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Update - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap UpStill a Buy? - MarketBeat
ImmunityBio stock gains 15% amid regulatory updates - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.2%What's Next? - MarketBeat
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval (Upgrade) (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.3%Here's Why - MarketBeat
D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
Why ImmunityBio, Inc. (IBRX) Is Skyrocketing - Insider Monkey
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details - Benzinga
ImmunityBio stock gains 15% amid regulatory updates (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances - MarketWatch
ImmunityBio shares surge following progress in FDA discussions By Investing.com - Investing.com Canada
ImmunityBio shares surge following progress in FDA discussions - Investing.com
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday - Benzinga
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom - BioSpace
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency - BioSpace
How to spot and prevent hypothermia - AOL
Why ImmunityBio, Inc. (IBRX) Is the Top Small Cap Stock to Buy with the Highest Upside Potential - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 5.2%Time to Sell? - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Sets New 12-Month LowHere's What Happened - MarketBeat
BTIG initiates ImmunityBio stock with Buy rating, cites potential of planned/underway studies By Investing.com - Investing.com South Africa
ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio gains unique J-code for bladder cancer treatment - Investing.com
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective - The Bakersfield Californian
As ImmunityBio's Bladder Cancer Drug Gains Ground, Will The Stock Pick Up Steam? - RTTNews
ImmunityBio (NASDAQ:IBRX) Trading 7% HigherHere's What Happened - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
ImmunityBio, Inc. (NASDAQ:IBRX) Shares Acquired by Barclays PLC - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Up 2.6%Time to Buy? - MarketBeat
IBRX Stock Hits 52-Week Low at $2.6 Amid Market Challenges - Investing.com
5 Companies That Celebrated First Approvals in 2024 - BioSpace
State Street Corp Purchases 790,408 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - MarketBeat
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):